The Future of Botox – PurTox and Xeomin
Future Non-Surgical Facelift Options: PurTox and Xeomin
An ideal non-surgical option for those without many wrinkles or sagging skin, liquid facelifts have been a boon for plastic surgeons looking to provide a minimally invasive anti-aging procedure. FDA-approved injectables include Botox, Collagen, and the recently approved Dysport. They all have great similarities and great differences, depending on your preference. However, if these options are not enough, dramatic advances in cosmetic surgery education and technology have given way to improved options for excellent facelift alternatives.
Recently featured in New Beauty Magazine, Xeomin and PurTox are said to be the newer faces of injectable treatments. Let’s take a closer look at both, which are awaiting FDA approval in 2010.
PurTox has had very positive reviews in clinical trials which, like Botox, is a prepared Botulinum Neurotoxin Type A. PurTox is essentially touted as the purest form of Botox, and is therefore believed to produce more natural and long-lasting results than the latest competitor. PurTox works by blocking muscle activity in the face, preventing the appearance of fine lines and wrinkles. A normal procedure can be done in 30 minutes or less and is believed to cost between $500 and $2500 per treatment, similar to Botox and Dysport. Like Botox and Dysport, PurTox side effects include the possibility of ptosis (droopy eyelid), swelling, bruising, and irritation or redness at the injection site.
Xeomin is one of the newer green options available among the current line of injectables. A prepared botulinum toxin already available for use in Europe, Xeomin lacks complexing proteins removed during a purification process. These proteins are thought to increase your immune system’s response to the substance and decrease the development of antibodies. Plus, Xeomin is stable at room temperature for three years, eliminating the need for refrigeration (which is why it’s considered an eco-friendly choice). Xeomin is not currently approved by the FDA, but awaits approval after completing clinical trials in the United States. Xeomin is also used to treat blepharospasm, a condition characterized by involuntary closing of the eyelids, and other conditions.